Richard Nkulikiyinka

Company: Bayer

Job title: Vice President, Head of Therapeutic Area Cardiology & Nephrology

Seminars:

Predicting Future Standard of Care with SGLT2 Inhibitors to Design Relevant Clinical Trials 8:30 am

What will the standard of care look like in drug development for CKD? Designing trials that will allow for the inclusion of novel therapies alongside SGLT2 inhibitors Considering the future standard of care: combining SGLT2 inhibitors with multiple therapiesRead more

day: Day Two

Panel Discussion: How can we Modernize Surrogate Endpoint Development? Moving Beyond Hard Endpoints 8:00 am

Evaluating novel surrogate endpoints in addition to emerging standard of care Non-invasive imaging, patient-reported outcomes, UACR, and more: what is an acceptable endpoint? Considering payers perspectives’ on moving beyond hard endpoints and ESRDRead more

day: Day One